Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study

Area of Science:

• Child and Adolescent Psychiatry
• Pharmacology
• Metabolic Health

Background:

• Risperidone is an atypical antipsychotic used in pediatric populations.
• Potential metabolic side effects, including weight gain and dyslipidemia, require investigation.
• Limited data exists on the specific impact of risperidone on metabolic parameters in youth.

Purpose of the Study:

• To evaluate changes in weight, triglyceride, and cholesterol levels in pediatric patients treated with risperidone.
• To identify potential correlations between weight changes and lipid alterations.
• To inform clinical practice regarding monitoring for metabolic disturbances.

Main Methods:

• Retrospective chart review of 22 child and adolescent inpatients.
• Analysis of demographic data, risperidone dosage, and duration of treatment.
• Statistical analysis using repeated measures ANOVA to assess changes in weight and lipid levels.

Main Results:

• Significant and clinically relevant weight gain averaging 7.0 kg was observed (p < 0.001).
• No significant changes in mean triglyceride or cholesterol levels were detected for the group.
• Weight gain was strongly correlated with triglyceride level changes (R2 = 0.22, p = 0.029), though this association diminished when excluding patients on lithium or divalproex.

Conclusions:

• Risperidone treatment in youth is associated with significant weight gain.
• Close monitoring of weight and regular laboratory assessment for lipid dysregulation is recommended for children and adolescents on risperidone.
• Further research is needed to clarify the long-term metabolic effects of risperidone and other atypical antipsychotics in this population.